VIR
Vir Biotechnology, Inc. Common Stock
Nasdaq · usd
Vir Biotechnology, Inc. Common Stock (VIR) trades at $9.25 (-3.44%) as of 7:30:02 PM EST on Nov 17, 2026, -9.40% over the past month. Market cap is $1.64B, with 11.9 days to cover in short interest.
Stock performance
How Vir Biotechnology, Inc. Common Stock (VIR) stock has performed from one day to one year, with its 52-week range.
- 1D
- -3.44%
- 1W
- -29.66%
- 1M
- -9.40%
- YTD
- +53.40%
- 1Y
- +68.18%
- 52-wk range
- $5.32 – $14.38
Key statistics
Today's trading snapshot for VIR: day range, open, previous close, volume and market cap.
- Day range
- $9.03 – $9.75
- Open
- $9.58
- Prev close
- $9.58
- Volume
- 3.48M
- Market cap
- $1.64B
- Shares out
- 171.27M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Vir Biotechnology, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 5.63
- P/B
- 1.90
- P/FCF
- —
- ROE
- -20.6%
- ROA
- -16.6%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 13, 2026
8-K filings
Material corporate events Vir Biotechnology, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Clinical trial resultsNov 9, 2026
Additional Week 96 data from the Phase 2 SOLSTICE trial show that treatment with elebsiran and tobevibart drove rapid HDV RNA suppression, with 100% (28/28) of patients who completed Week 96 of combination therapy reaching undetectable viremia. Among patients with paired liver stiffness measurements, 89% (24/27) had improved or stable liver stiffness at Week 96.
- Quarterly earningsNov 4, 2026
On November 4, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Director appointmentOct 28, 2026
On October 26, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) ... approved an increase in the size of the Board from eight to nine members and the appointment of Suzanne Topalian, M.D., to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders ... effective as of October 27, 2026.
- Partnership or collaborationOct 14, 2026
On October 9, 2026, Vir Biotechnology, Inc. (Vir Bio) and Gilead Sciences, Inc. (Gilead) entered into a Collaboration and License Agreement (the Agreement), pursuant to which Vir Bio and Gilead will enter into a global strategic collaboration to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens.
- Partnership or collaborationOct 8, 2026
VIR-5500 is being co-developed by Astellas Pharma Inc. and the Company through a global strategic collaboration.
VIR short interest
How heavily VIR is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 11.9
- Short interest
- 16.87M
- Avg volume
- 1.42M
As of · reported to FINRA twice monthly.
VIR news
The latest news and headlines about Vir Biotechnology, Inc. Common Stock (VIR).
- Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should KnowpositiveZacks Investment Research· Nov 9, 2026
- Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?positiveZacks Investment Research· Oct 29, 2026
- Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?neutralZacks Investment Research· Oct 15, 2026
- Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallypositiveThe Motley Fool· May 23, 2026
- "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiespositiveGlobeNewswire Inc.· May 14, 2026
Frequently asked questions
What is the Vir Biotechnology, Inc. Common Stock (VIR) stock price today?
Vir Biotechnology, Inc. Common Stock (VIR) is trading at $9.25 (-3.44% on the day) as of 7:30:02 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Vir Biotechnology, Inc. Common Stock?
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer.
What is the short interest in VIR?
As of Oct 30, 2026, VIR has 16.87M shares short and 11.9 days to cover.
What exchange is VIR listed on?
Vir Biotechnology, Inc. Common Stock (VIR) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of VIR with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a VIR analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.